No Data
No Data
CMB International: bullish on the rebound of Mainland China's pharmaceutical industry, with continued bullish policy implementation.
Zhaojin International continues to be bullish on Shenzhen Mindray Bio-Medical Electronics, United Imaging Medical, Innovent Bio (01801), Beigene (06160), Genscript Biotech (02273), Kelun Pharma (06990), and Anpac Bio-Medical Science (02367).
HTSC: Different performance for beauty and medical beauty in Q2. Q3 may be more challenging for new product sales during off-season.
In Q3 24, it is the off-season for the industry, but also an important window period for many brand manufacturers to prepare for the November 11 shopping festival. It is recommended to pay close attention to new product developments.
We Ran A Stock Scan For Earnings Growth And Giant Biogene Holding (HKG:2367) Passed With Ease
Tracking Hong Kong stocks | Rise of domestic cosmetics in the market, institutions are bullish on top companies' penetration rate improvement (attached concept stocks).
Cosmetics lead the domestic industry growth, with market share continuing to rise.
HK Stocks Market | Juzi Bio (02367) rose over 3%, domestic products with improved quality-price ratio, company is expected to achieve a double play in the beauty and medical aesthetics business.
Zhītōng Finance APP learned that Juzi Biotech (02367) rose more than 3%, and as of press time, it has risen by 3.12% to HKD 41.90, with a turnover of HKD 60.6538 million. Swhy released research reports stating that as the domestic product's "quality-price ratio" increases, affordable consumption rises, and the penetration rate of mass markets increases, the bullish large single-product viscosity is strong, and the channel layout is diversified. The medical and aesthetic industry will continue to benefit from the rich supply of products on the supply side, and the industry will maintain healthy and standardized development. The bank pointed out that the restructuring collagen protein track is hot, which has helped the company's brand and category develop rapidly. It is expected that Juzi biotech's 24 H1 revenue growth rate will be about 43%.
Swhy: The penetration rate continues to increase coupled with the rise of domestic products, bullish on the cosmetic and medical beauty sector.
The medical beauty industry will continue to benefit from a rich supply of products and maintain healthy development through industry standardization.
No Data